Piribedil

From Self-sufficiency
Revision as of 06:15, 7 May 2010 by Boghog2 (Talk) (turned on IUPHAR parameter)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Piribedil
File:Piribedil.svg
Systematic (IUPAC) name
2-[4-(benzo[1,3]dioxol-5-ylmethyl)piperazin-1-yl]pyrimidine
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Biological half-life 1.7-6.9 hours
Excretion Renal (68%) and biliary (25%)
Identifiers
CAS Number 3605-01-4
ATC code N04BC08 (WHO)
PubChem CID 4850
IUPHAR/BPS 49
Chemical data
Formula C16H18N4O2
Molar mass 298.340 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Piribedil (trade names Trivastal, Pronoran, Trastal, Trivastan) is an antiparkinsonian agent and piperazine derivative which acts as a D2 and D3 receptor agonist. It also has α2-adrenergic antagonist properties.[1][2]

Indications

Other uses

The drug has been shown to enhance working memory capacities in normal aging adults.[3]

In age-related memory impairment, it has a positive effect on psychophysiological state of elderly people, improving memory and attention and increasing the velocity of psychomotor reactions and lability of nervous processes.[4]

It enhances cognitive skill learning in healthy older adults.[5]

It showed a positive effect in restless legs syndrome [6]

Dosage

Parkinson's disease

Administration of piribedil should be initiated with one tablet daily during the first week. Dosage should then be gradually increased every week until achieving the optimal therapeutic dose:

  • as monotherapy: three to five tablets in three to five doses daily.
  • in combination with L-dopa therapy: one to three tablets daily.

Other indications

One tablet daily at the end of the main meal. In severe cases: two tablets daily in two doses.

Adverse effects

Interactions

Dopamine antagonists reduce the effect of piribedil.

Overdose

At very high doses, piribedil has an emetic action on the chemoreceptor trigger zone (CTZ). Tablets will thus be rapidly rejected, which explains why no data are currently available concerning the risk of overdosage.

Receptor affinities

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


Dopaminergics
Anticholinergics
Others
de:Piribedil
  1. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. ↑ Gierski, F.; Peretti, C.; Ergis, A. (30 January 2007). "Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 31 (1): 262–268. doi:10.1016/j.pnpbp.2006.06.017. PMID 16876301.  edit
  4. ↑ Bochkarev, VK; Faĭzulloev, AZ; Avedisova, AS (2005). "Efficacy of pronoran in age-related memory impairment". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov. 105 (2): 46–50. PMID 15792142.  edit
  5. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found. edit
  6. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found. edit
  7. ↑ 7.0 7.1 Schubert-Zsilavecz, M. "Piribedil". Neue Arzneimittel 2008 (in German). 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Piribedil&oldid=24132"